Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43207   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-004355-40
    Sponsor's Protocol Code Number:rhLAMAN-04
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-01-18
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2011-004355-40
    A.3Full title of the trial
    A multi-center, open-label trial of the long-term efficacy and safety of Lamazym for the treatment of patients with alpha-Mannosidosis.
    Multizentrische, offene Studie zur Langzeitwirkung und sicherheit der Behandlung von Patienten mit Alpha-Mannosidose mit Lamazym
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A multi-center, open-label trial of the long-term efficacy and safety of Lamazym for the treatment of patients with alpha-Mannosidosis.
    Multizentrische, offene Studie zur Langzeitwirkung und sicherheit der Behandlung von Patienten mit Alpha-Mannosidose mit Lamazym
    A.3.2Name or abbreviated title of the trial where available
    Phase 2b
    Studienphase: 2b
    A.4.1Sponsor's protocol code numberrhLAMAN-04
    A.5.4Other Identifiers
    Name:EudraCTNumber:2011-004355-40
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorZymenex A/S
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEU FP7 ALPHA-MAN
    B.4.2CountryEuropean Union
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationZymenex A/S
    B.5.2Functional name of contact pointCEO
    B.5.3 Address:
    B.5.3.1Street AddressRoskildevej 12C
    B.5.3.2Town/ cityHillerod
    B.5.3.3Post codeDK-3400
    B.5.3.4CountryDenmark
    B.5.4Telephone number+4548250054
    B.5.5Fax number+4548251054
    B.5.6E-mailzxmail@zymenex.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/04/260
    D.3 Description of the IMP
    D.3.1Product nameLamazym
    D.3.2Product code rhLAMAN
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor coderhLAMAN
    D.3.9.3Other descriptive namerecombinant human alpha-mannosidase
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number1.8 to 2.2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Treatement of Alpha-Mannosidosis
    Behandlung von Alpha-Mannosidose
    E.1.1.1Medical condition in easily understood language
    The scientific study is a treatment process lasting 6 months with patients suffering from the disease known as alpha-mannosidosis.
    Diese klinische Studie umfasst einen Behandlungsverlauf mit einer Dauer von sechs Monaten mit Patienten, die an der Krankheit Alpha-Mannosidose leiden.
    E.1.1.2Therapeutic area Diseases [C] - Nutritional and Metabolic Diseases [C18]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The overall objective of this trial is the evaluation of long-term efficacy, safety and tolerability of Lamazym treatment in patients with alpha-Mannosidosis.
    The primary objectives of the trial are:
    Evaluation of long-term efficacy from baseline of Lamazym on reduction of the biomarker Oligosaccharides in blood and CSF and an improvement in the 3 minute stair climb, 6 minute walk test and pulmonary function from baseline.
    Die Studie dient der Beurteilung der Langzeitwirksamkeit, sicherheit und verträglichkeit einer Lamazym-Therapie für Patienten mit Alpha-Mannosidose.
    Primäres Ziel der Studie:
    Beurteilung der Langzeitwirksamkeit von Lamazym im Vergleich zur Baseline bei der Senkung des Biomarkers Oligosaccharide in Blut und CSF und der Verbesserung des 3-Minuten-Treppensteigentests, des 6-Minuten-Gehtests und der Lungenfunktionsprüfung im Vergleich zur Baseline
    E.2.2Secondary objectives of the trial
    The secondary objectives of the trial are:
    To evaluate the long-term safety profile of Lamazym
    Evaluation of efficacy of Lamazym on:
    o The clinical parameters BOT2 and Hearing
    o The CSF biomarkers (Tau, NFLp, GFAp)
    o The cognitive development tested by Leiter R
    o The CNS improvement measured with MRI/MRS





    Sekundäre Ziele der Studie:
    Beurteilung des Langzeitsicherheitsprofils von Lamazym
    Beurteilung der Wirksamkeit von Lamazym bei:
    o den klinischen Parametern BOT2 und Hören
    o den CSF-Biomarkern (Tau, NFp, GFAp)
    o der kognitiven Entwicklung, ermittelt mithilfe von Leiter R
    o der ZNS-Verbesserung, ermittelt mithilfe von MRT/MRS
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    The subject must have participated in the phase 1 trial (EudraCT number: 2010-022084-36) and phase 2a trial (EudraCT number: 2010-022085-26)
    Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)
    The subject and his/her guardian(s) must have the ability to comply with the protocol
    Patienten müssen die folgenden Kriterien erfüllen, um in die Studie eingeschlossen zu werden:
    Der Patient muss an der Phase-1-Studie (EudraCT-Nummer: 2010-022084-36) und der Phase-2a-Studie (EudraCT-Nummer: 2010-022085-26) teilgenommen haben
    Der Patient bzw. dessen gesetzliche(r) Vertreter müssen vor der Durchführung. studienbezogener Maßnahmen (studienbezogene Maßnahmen sind Prozeduren, die nicht im Rahmen der normalen Behandlung des Patienten nicht erfolgen würden) eine unterzeichnete Einwilligungserklärung vorlegen.
    Der Patient bzw. dessen gesetzliche(r) Vertreter müssen in der Lage sein, den Studienplan zu befolgen.
    E.4Principal exclusion criteria
    The subject cannot walk without support
    Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis
    History of bone marrow transplantation
    Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial
    Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial.
    Pregnancy
    Psychosis within the last 3 months
    Planned major surgery that, in the opinion of the investigator, would preclude participation in the trial
    Participation in other interventional trials testing IMP except for studies with Lamazym
    Patienten werden von der Studie ausgeschlossen, wenn sie die Einschlusskriterien nicht erfüllen oder wenn eines der folgenden Kriterien zutrifft:
    Der Patient kann nur mit Unterstützung gehen
    Bekannte Chromosomenanomalie und Syndrome (angeborene Krankheiten) abgesehen von Alpha-Mannosidose, die die psychische und motorische Entwicklung hemmen
    Zurückliegende Stammzelltransplantation
    Bekannte klinisch relevante kardiovaskuläre, hepatische, pulmonale oder renale Krankheit oder andere Erkrankung, die nach Meinung des Prüfarztes eine Nichtteilnahme an der Studie begründet
    Möglicher anderer medizinischer Zustand oder schwere interkurrente Krankheit oder andere Umstände, der bzw. die nach Meinung des Prüfarztes eine Nichtteilnahme an der Studie begründet
    Schwangerschaft
    Psychose innerhalb der letzten drei Monate
    Geplante größere Operation, die nach Meinung des Prüfarztes eine Nichtteilnahme an der Studie begründet
    Teilnahme an einer anderen Interventionsstudie zur Untersuchung eines Arzneimittels, ausgenommen Studien mit Lamazym
    E.5 End points
    E.5.1Primary end point(s)
    Primary Endpoint evaluation as change from baseline on Reduction of Oligosaccharides in blood serum and CSF and an improvement in the 3 minute stair climb, 6 minute walk test and pulmonary function
    Beurteilung des primären Endpunkts im Vergleich zur Baseline:
    Senkung der Oligosaccharide in Blutserum und CSF und Verbesserung des 3-Minuten-Treppensteigentests, des 6-Minuten-Gehtests und der Lungenfunktionsprüfung
    E.5.1.1Timepoint(s) of evaluation of this end point
    Efficacy will be assessed at the Danish site as interim (January/February 2012) and as end evaluation (minimum 26 weeks post trial initiation).
    Die Beurteilung der Wirksamkeit erfolgt am dänischen Prüfzentrum im Rahmen einer Zwischenuntersuchung (Januar/Februar 2012) und einer Abschlussuntersuchung (mindestens 26 Wochen nach Studienbeginn).
    E.5.2Secondary end point(s)
    Safety Endpoints measured throughout the trial of:
    Development of adverse events
    Development of clinically significant changes in vital signs and change in physical examination
    Development of clinically significant changes in the clinical laboratory parameters (hematology, biochemistry and urinalysis)
    Development of rhLAMAN antibodies and neutralizing/inhibitory antibodies

    Secondary Efficacy Endpoints evaluation as change from baseline on:
    CNS parameters: Reduced concentration of mannose-rich oligosaccharides in brain tissue as measured by MRS visual score, reduction of MRI diffusion coefficient in white matter, gray matter and centrum semi oval and Improved Cerebrospinal fluid neuro-degeneration biomarker (Tau, NFLp, GFAp)
    Clinical parameters: Improved functional capacity on the BOT2 and reduced hearing loss
    Cognitive ability: Improved age equivalence with Leiter R
    In addition, the CHAQ, filled by the subject’s guardian, will be evaluated
    Sicherheitsendpunkte, ermittelt im Laufe der Studie anhand von:
    Auftreten von unerwünschten Ereignissen
    Auftreten von klinisch relevanten Veränderungen der Vitalzeichen und Veränderungen bei der körperlichen Untersuchung
    Auftreten von klinisch relevanten Veränderungen der klinischen Laborwerte (Hämatologie, Blutchemie und Urin)
    Auftreten von rhLAMAN-Antikörpern und neutralisierenden/inhibitorischen Antikörpern

    Bewertung der sekundären Wirksamkeitsendpunkte als Veränderung zur Baseline:
    ZNS-Parameter: Geringere Konzentration mannosereicher Oligosaccharide im Hirngewebe, ermittelt mithilfe visueller MRT-Scores, Verkleinerung des MRT-Diffusionskoeffizienten in der Substantia alba, der Substantia grisea und dem Centrum semiovale und bessere neurodegenerative Biomarker (Tau, NFp, GFAp) in der Rückenmarkflüssigkeit
    Klinische Parameter: Funktionsverbesserungen bei BOT2 und geringerer Hörverlust
    Kognitive Fähigkeiten: Verbesserte Altersäquivalenz anhand von Leiter R
    Darüber hinaus wird der vom Sorgeberechtigten des Patienten ausgefüllte CHAQ beurteilt
    E.5.2.1Timepoint(s) of evaluation of this end point
    Safety will be assessed at every visit.
    Efficacy will be assessed at the Danish site as interim (January/February 2012) and as end evaluation (minimum 26 weeks post trial initiation).
    Die Sicherheit wird bei jedem Besuch beurteilt.
    Die Beurteilung der Wirksamkeit erfolgt am dänischen Prüfzentrum im Rahmen einer Zwischenuntersuchung (Januar/Februar 2012) und einer Abschlussuntersuchung (mindestens 26 Wochen nach Studienbeginn).
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA7
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last patient Last visit
    Letzter Besuch des letzten Patienten
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 8
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 3
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 5
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    One female of 15-17 year is tested monthly (HCG)
    Due to the disease related mental retardation the subjects are under gardianship of the parents
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 9
    F.4.2.2In the whole clinical trial 9
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Given no safety concerns have arisen, the subjects will be offered to continue to receive the investigational medicinal product (IMP) on a post-study care base in the home country until the product is available on the market or until the sponsor decides to terminate the project (e.g. for safety reasons).
    Werden keine Sicherheitsbedenken laut, wird den Patienten im Rahmen eines Post-study-care-Programms die Fortsetzung der Behandlung mit der Prüfmedikation (IMP) in ihrem Heimatland angeboten, bis das Arzneimittel im Handel erhältlich ist oder der Sponsor einen Abbruch des Projekts, beispielsweise aus Sicherheitsgründen, beschließt.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-03-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-07-23
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2013-09-20
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA